Compare Amphastar Pharmaceuticals Inc (AMPH) vs Twilio Inc (TWLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Twilio Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.74 (market cap $826.08M), while Twilio Inc trades at $215.3 (market cap $32.56B). The key difference: Twilio Inc is far larger — about 39.4× Amphastar Pharmaceuticals Inc's market cap, and Twilio Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | TWLO | |
|---|---|---|
Market Cap | $826.08M | $32.56B |
Sector | Health | Technology |
52-Week High | $30.81 | $236.64 |
52-Week Low | $16.87 | $92.44 |
Enterprise Value | $1.22B | $31.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Twilio trades at $214.56, down 1.85% on the day, with a bullish technical outlook from moving averages but overbought RSI signals. The company shows improving fundamentals with revenue growth to $5.07B in 2025 and a return to net profitability. Recent earnings beats and positive analyst sentiment, including a Goldman Sachs buy initiation at $300 (June 24, 2026), highlight momentum in AI-driven cloud communications.
Outlook remains positive given strong earnings beats and margin expansion potential, but high valuation multiples (P/E 325.09) pose risks if growth slows. Investors face execution risks in competitive SaaS markets and sensitivity to tech sector volatility. Wall Street consensus is bullish with 75% buy ratings and a $215.14 price target, near current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →
